Accelerated phase chronic myeloid leukaemia or intolerant to prior tyrosine kinase Cost no inhibitor; no capped Nov no Ponatinib Iclusig® Aus 7 Yes Philadelphia 2 no funding at 2014 July no registration $23,000 2015 funding positive acute leukaemia resistant or intolerant to prior tyrosine kinase inhibitor $500 per Nov stromal month 2013 for no no Aus and tumour; for first mCRC, Sept Regorafenib Stivarga® 9 Yes 23 July 2014 no funding NZ metastatic 12 March no 2014 no and March colorectal months 2015 for funding funding 2015 cancer then GIST free
Ponatinib Iclusig® Aus 7 Yes Accelerated phase chronic myeloid leukaemia or intolerant to prior tyrosine kinase inhibitor; Philadelphia positive acute leukaemia resistant or intolerant to prior tyrosine kinase inhibitor 2 Cost capped at $23,000 Nov 2014 July 2015 no no funding no no funding no registration Regorafenib Stivarga® Aus and NZ 9 Yes stromal tumour; metastatic colorectal cancer 23 $500 per month for first 12 months then free Nov 2013 for mCRC, March 2015 for GIST July 2014 and March 2015 no no funding Sept 2014 no funding no no funding
1-s2.0-S0168851017303457-mmc1.docx